• FirefoxUpgrade to the new Firefox »
  •  Dow Down1.45% Nasdaq Down1.03%

    More On OXB.L



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Oxford BioMedica PLC (OXB.L)

    7.00 0.00(0.00%) Jan 30, 11:23AM EST
    Add to Portfolio
    ProfileGet Profile for:
    Oxford BioMedica PLC
    Medawar Centre
    Robert Robinson Avenue
    Oxford, OX4 4GA
    United Kingdom - Map
    Phone: 44 18 6578 3000
    Fax: 44 18 6578 3001
    Website: http://www.oxfordbiomedica.co.uk

    Index Membership:N/A
    Full Time Employees:106

    Business Summary 

    Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Oxford BioMedica PLC

    Key Executives 
    Mr. John Dawson , 55
    Chief Exec. Officer and Director
    Mr. Timothy William Watts , 57
    Chief Financial Officer, Company Sec. and Director
    Dr. Paul Blake M.D., 67
    Chief Devel. Officer, Director, Chairman of Remuneration Committee and Member of Nomination Committee
    Mr. Peter Nolan , 62
    Chief Bus. Officer and Exec. Director
    Lara Mott ,
    Head of Corp. Communications
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.